1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Herbert, A.P. Deakin, J.A. Schmidt, C.Q. Blaum, B.S. Egan, C. Ferreira, V.P. Pangburn, M.K. Lyon, M. Uhrin, D. Barlow, P.N. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J. Biol. Chem. JBCHA3 0071 0021-9258 282 18960 18968 10.1074/jbc.M609636200 17360715 Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism. 2007 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 6985.064 COMPLEMENT FACTOR H CCP MODULE 7, RESIDUES 386-446 1 man polymer H FACTOR 1 no no LRKCYFPYLENGYNQNHGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVK LRKCYFPYLENGYNQNHGRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVK A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS 4922 PICHIA PASTORIS KM71H PPICZALPHAB citation pdbx_nmr_spectrometer repository Initial release Version format compliance Version format compliance Data collection Database references 1 0 2007-03-20 1 1 2011-05-08 1 2 2011-07-13 1 3 2018-05-02 _citation.journal_abbrev _citation.page_last _citation.pdbx_database_id_DOI _citation.title _pdbx_nmr_spectrometer.model C3D AND HEPARIN BINDING COMPLEMENT FACTOR H DOMAINS SCR19-20 FOUR MODELS OF HUMAN FACTOR H DETERMINED BY SOLUTION SCATTERING CURVE-FITTING AND HOMOLOGY MODELLING FACTOR H, 15TH AND 16TH C-MODULE PAIR ( NMR, MINIMIZED AVERAGED STRUCTURE) FACTOR H, 15TH C-MODULE PAIR (NMR, MINIMIZED AVERAGED STRUCTURE) HOMOLOGY MODEL OF HUMAN FACTOR H SCRS 6 AND 7 SOLUTION STRUCTURE OF THE PRIMARY HOST RECOGNITION REGION OF COMPLEMENT FACTOR H STRUCTURE OF HUMAN COMPLEMENT FACTOR H CARBOXYL TERMINALDOMAINS 19-20: A BASIS FOR ATYPICAL HEMOLYTIC UREMICSYNDROME STRUCTURE OF CCP MODULE 7 OF COMPLEMENT FACTOR H - THE AMD NOT AT RISK VARIENT (402Y) PDBE Y PDBE 2007-02-16 REL PROTEIN SEGMENT CONTAINING THE COMMON HIS VARIENT AT POSITION 402 THE STRUCTURE WAS DETERMINED USING TRIPLE-RESONANCE NMR SPECTROSCOPY ON 13C, 15N-LABELED FACTOR H CCP 7(402H) LOWEST OVERALL ENERGY 50 20 CBCACONH CBCANH H_CCONH TOCSY HCCH TOCSY HNCO 15N EDITED TOCSY HSQC HBHACONH HBHANH C_CCONH TOCSY HBCBCGCDCEHE HBCBCGCDHD 20 mM 5.2 pH 1.0 atm 298.0 K 20 mM 5.2 pH 1.0 atm 298.0 K REFINEMENT DETAILS CAN BE FOUND IN THE JRNL CITATION ARIA 2.0 1 10% WATER/90% D2O BRUNGER,ADAMS,CLORE,DELANO,GROS, GROSSE- KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU,READ, RICE,SIMONSON,WARREN refinement CNS 1.1 structure solution CCPNMR ANALYSIS ANALYSIS 600 Bruker Avance 800 Bruker Avance LEU 386 n 1 LEU 386 A ARG 387 n 2 ARG 387 A LYS 388 n 3 LYS 388 A CYS 389 n 4 CYS 389 A TYR 390 n 5 TYR 390 A PHE 391 n 6 PHE 391 A PRO 392 n 7 PRO 392 A TYR 393 n 8 TYR 393 A LEU 394 n 9 LEU 394 A GLU 395 n 10 GLU 395 A ASN 396 n 11 ASN 396 A GLY 397 n 12 GLY 397 A TYR 398 n 13 TYR 398 A ASN 399 n 14 ASN 399 A GLN 400 n 15 GLN 400 A ASN 401 n 16 ASN 401 A HIS 402 n 17 HIS 402 A GLY 403 n 18 GLY 403 A ARG 404 n 19 ARG 404 A LYS 405 n 20 LYS 405 A PHE 406 n 21 PHE 406 A VAL 407 n 22 VAL 407 A GLN 408 n 23 GLN 408 A GLY 409 n 24 GLY 409 A LYS 410 n 25 LYS 410 A SER 411 n 26 SER 411 A ILE 412 n 27 ILE 412 A ASP 413 n 28 ASP 413 A VAL 414 n 29 VAL 414 A ALA 415 n 30 ALA 415 A CYS 416 n 31 CYS 416 A HIS 417 n 32 HIS 417 A PRO 418 n 33 PRO 418 A GLY 419 n 34 GLY 419 A TYR 420 n 35 TYR 420 A ALA 421 n 36 ALA 421 A LEU 422 n 37 LEU 422 A PRO 423 n 38 PRO 423 A LYS 424 n 39 LYS 424 A ALA 425 n 40 ALA 425 A GLN 426 n 41 GLN 426 A THR 427 n 42 THR 427 A THR 428 n 43 THR 428 A VAL 429 n 44 VAL 429 A THR 430 n 45 THR 430 A CYS 431 n 46 CYS 431 A MET 432 n 47 MET 432 A GLU 433 n 48 GLU 433 A ASN 434 n 49 ASN 434 A GLY 435 n 50 GLY 435 A TRP 436 n 51 TRP 436 A SER 437 n 52 SER 437 A PRO 438 n 53 PRO 438 A THR 439 n 54 THR 439 A PRO 440 n 55 PRO 440 A ARG 441 n 56 ARG 441 A CYS 442 n 57 CYS 442 A ILE 443 n 58 ILE 443 A ARG 444 n 59 ARG 444 A VAL 445 n 60 VAL 445 A LYS 446 n 61 LYS 446 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N CYS 389 A N CYS 4 A O PHE 406 A O PHE 21 A N TYR 398 A N TYR 13 A O ALA 415 A O ALA 30 A N ILE 412 A N ILE 27 A O VAL 429 A O VAL 44 A N ALA 421 A N ALA 36 A O ILE 443 A O ILE 58 1 A A HD21 HZ ASN PHE 401 406 1.11 7 A A HA HG2 VAL PRO 429 438 1.32 8 A A HA HG2 VAL PRO 429 438 1.30 9 A A O H ASN ASN 399 401 1.57 13 A A HB3 HB2 ASN HIS 399 402 1.24 16 A A HZ H PHE PHE 391 406 1.16 16 A A HA HG2 VAL PRO 429 438 1.29 17 A A O HD1 PHE HIS 391 402 1.60 19 A A HH HG12 TYR VAL 398 414 1.13 20 A A HA HG2 VAL PRO 429 438 1.28 1 A PRO 392 -75.40 -168.94 1 A ILE 412 -170.43 135.90 1 A GLU 433 -175.21 -65.31 1 A THR 439 68.87 110.03 2 A ASN 396 -146.76 47.03 2 A GLU 433 -174.70 -67.16 2 A ASN 434 -106.53 44.78 2 A THR 439 66.82 112.74 2 A PRO 440 -61.10 99.17 2 A VAL 445 -93.15 45.16 3 A GLU 433 -175.90 -59.84 3 A ASN 434 -95.28 35.71 3 A THR 439 68.68 117.74 3 A PRO 440 -69.62 82.72 4 A GLU 395 63.83 -83.50 4 A ILE 412 -170.06 139.16 4 A GLU 433 -177.01 -75.01 4 A THR 439 65.38 103.12 4 A PRO 440 -69.69 80.00 4 A CYS 442 -56.16 99.26 5 A ARG 387 -68.15 50.38 5 A PRO 392 -76.97 -166.18 5 A ILE 412 -172.23 139.06 5 A MET 432 -85.88 -153.00 5 A ASN 434 -107.84 62.12 5 A THR 439 68.05 111.05 5 A PRO 440 -58.29 83.06 6 A PRO 423 -58.41 4.20 6 A GLU 433 -178.83 -62.82 6 A ASN 434 -87.55 40.86 6 A THR 439 71.14 112.64 7 A PRO 392 -76.20 -166.77 7 A ASN 399 -96.86 47.87 7 A GLU 433 -176.03 -77.02 7 A THR 439 70.62 103.57 8 A LEU 394 -99.70 55.16 8 A GLU 395 59.57 -86.53 8 A ASN 399 34.41 71.38 8 A ILE 412 -176.49 138.52 8 A GLU 433 -168.48 -70.00 8 A THR 439 62.50 96.66 8 A PRO 440 -69.79 86.00 8 A ARG 441 -151.05 87.10 9 A ASN 399 72.83 -63.74 9 A GLN 400 56.33 -41.26 9 A ILE 412 -172.67 135.93 9 A LYS 424 72.47 30.55 9 A THR 439 65.77 97.89 10 A ARG 387 -40.10 80.88 10 A ASN 396 -112.56 50.96 10 A GLU 433 -169.51 -70.82 10 A THR 439 72.63 116.32 10 A CYS 442 -68.93 84.16 11 A ILE 412 -174.49 146.63 11 A LYS 424 -89.21 33.31 11 A MET 432 -94.31 -157.60 11 A ASN 434 -84.81 46.09 11 A THR 439 67.49 109.22 12 A PRO 423 -59.52 -0.50 12 A ASN 434 -93.81 36.23 12 A THR 439 66.42 121.05 12 A PRO 440 -64.94 89.64 13 A ASN 401 -140.70 45.49 13 A ILE 412 179.95 127.31 13 A ASN 434 -87.32 31.60 13 A THR 439 73.21 107.23 14 A MET 432 -89.81 -157.46 14 A THR 439 67.72 108.22 15 A ASN 396 72.70 -9.74 15 A ASN 399 -98.46 47.01 15 A ILE 412 -171.47 135.48 15 A LYS 424 -84.69 43.32 15 A ASN 434 -97.68 46.25 15 A THR 439 71.11 123.57 15 A PRO 440 -65.62 92.75 16 A TYR 393 -51.76 106.08 16 A MET 432 -84.83 -151.76 16 A THR 439 68.08 108.83 17 A ASN 396 -153.38 22.47 17 A ILE 412 -173.52 140.93 17 A PRO 423 -54.36 -119.17 17 A GLN 426 79.32 -148.33 17 A ASN 434 -118.03 51.06 17 A THR 439 71.81 110.14 18 A LYS 388 58.32 162.22 18 A ASN 396 -106.60 48.88 18 A ALA 425 -149.68 40.76 18 A THR 427 -150.61 -4.47 18 A GLU 433 -173.77 -64.25 18 A ASN 434 -84.21 30.28 18 A THR 439 68.00 111.53 18 A PRO 440 -60.79 97.92 19 A ARG 387 52.53 18.31 19 A GLU 395 -44.17 -78.10 19 A ASN 396 -100.89 42.00 19 A ASN 399 -79.94 42.59 19 A ILE 412 -170.29 135.70 19 A CYS 416 44.17 144.46 19 A MET 432 -90.51 -157.32 19 A ASN 434 -99.63 51.80 19 A THR 439 69.61 113.40 20 A ARG 387 -101.46 79.62 20 A ASN 396 -134.06 -31.81 20 A TYR 398 39.73 26.76 20 A ASN 399 -102.77 43.60 20 A ILE 412 -170.31 146.46 20 A THR 439 64.25 102.86 20 A ARG 441 -153.57 74.65 COMPLEMENT FACTOR H Structure of CCP module 7 of complement factor H - The AMD at risk varient (402H) 1 N N A PRO 423 A PRO 38 HELX_P A ALA 425 A ALA 40 5 1 3 disulf 2.029 A CYS 389 A SG CYS 4 1_555 A CYS 431 A SG CYS 46 1_555 disulf 2.030 A CYS 416 A SG CYS 31 1_555 A CYS 442 A SG CYS 57 1_555 IMMUNE RESPONSE AGE RELATED MACULAR DEGENERATION, AGE-RELATED MACULAR DEGENERATION, DISEASE MUTATION, GLYCOSAMINOGLYCAN, ALTERNATIVE SPLICING, COMPLEMENT ALTERNATE PATHWAY, GLYCOPROTEIN, INNATE IMMUNITY, IMMUNE RESPONSE, SUSHI, FACTOR H, COMPLEMENT, POLYMORPHISM CFAH_HUMAN UNP 1 P08603 386 446 2JGW 386 446 P08603 A 1 1 61 2 2 2 2 anti-parallel anti-parallel anti-parallel anti-parallel A CYS 389 A CYS 4 A TYR 390 A TYR 5 A LYS 405 A LYS 20 A PHE 406 A PHE 21 A GLY 397 A GLY 12 A TYR 398 A TYR 13 A ALA 415 A ALA 30 A CYS 416 A CYS 31 A SER 411 A SER 26 A ASP 413 A ASP 28 A THR 428 A THR 43 A THR 430 A THR 45 A TYR 420 A TYR 35 A ALA 421 A ALA 36 A ILE 443 A ILE 58 A ARG 444 A ARG 59 1 P 1